A director at Orica Limited bought 3,970 shares at 17.999AUD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
The general evaluation of ORICA (AU), a company active in the Speciality Chemicals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 15, 2022, the closing price was AUD 1...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
We have discontinued coverage of Oriflame as the company is in the process of being bought and delisted following an offer to purchase all outstanding shares by its main shareholders. The final day of trading is expected to be 17 July. Our last published recommendation, target price and estimates should no longer be relied upon.
Oriflame’s Q1 figures reflected stable to slightly growing underlying operations in three divisions and a challenging environment for Asia & Turkey. Revenues were below our estimate while adj EBIT was above on higher margins for CIS and Europe & Africa. EPS was lifted by lower net financials. We reiterate our BUY recommendation and SEK270 target price.
We make no change to our AUD 16.50 fair value estimate for no-moat Orica, still anticipating material margin expansion due to mix shift and cost efficiencies. First-half fiscal 2019 EBITDA expansion to 15.4% from 14.9% in the previous corresponding period highlights this potential, and we expect there is more to come. Underlying first-half fiscal 2019 NPAT increased 35% to AUD 167 million, though below our AUD 197 million forecast. Expected ammonium nitrate, or AN, price appreciation was a key d...
Orica is a leading provider of explosives to the global mining industry. It also provides underground mining and tunneling products, but this business has struggled for an extended period. Strong technological knowledge, strict regulatory requirements, global scale, and a duopoly position in the key Australian explosives market are competitive strengths. Demand for resources drives fundamentals, and growth is linked to mining volumes. Cost-reduction initiatives from mining customers will feature...
We make no change to our AUD 16.50 fair value estimate for no-moat Orica, still anticipating material margin expansion due to mix shift and cost efficiencies. First-half fiscal 2019 EBITDA expansion to 15.4% from 14.9% in the previous corresponding period highlights this potential, and we expect there is more to come. Underlying first-half fiscal 2019 NPAT increased 35% to AUD 167 million, though below our AUD 197 million forecast. Expected ammonium nitrate, or AN, price appreciation was a key d...
We make no change to our AUD 16.50 fair value estimate for no-moat Orica. There are no changes to long-term assumptions, nor to our AUD 418 million underlying fiscal 2019 earnings forecast. This anticipates continued ammonium nitrate, or AN, volume growth from Australia Pacific, with Bontang plant expansion due to stronger demand, and comes despite well publicised delays from the Burrup plant to first-half 2020. North American and EMEA volumes are still anticipated to grow into fiscal 2019 with ...
We expect focus in the Q1 report (due at 07:15 CET on 9 May) to be on headline revenues, margins, Q2 sales QTD and the performance of the Asia & Turkey division. We will also look for confirmation of the recent growth trend seen in the other three regions, including YOY growth for registered actives. We find the valuation attractive, and reiterate our BUY recommendation and SEK270 target price.
We make no change to our AUD 16.50 fair value estimate for no-moat Orica. There are no changes to long-term assumptions, nor to our AUD 418 million underlying fiscal 2019 earnings forecast. This anticipates continued ammonium nitrate, or AN, volume growth from Australia Pacific, with Bontang plant expansion due to stronger demand, and comes despite well publicised delays from the Burrup plant to first-half 2020. North American and EMEA volumes are still anticipated to grow into fiscal 2019 with ...
We make no change to our AUD 16.50 fair value estimate for no-moat Orica. There are no changes to long-term assumptions, nor to our AUD 418 million underlying fiscal 2019 earnings forecast. This anticipates continued ammonium nitrate, or AN, volume growth from Australia Pacific, with Bontang plant expansion due to stronger demand, and comes despite well publicised delays from the Burrup plant to first-half 2020. North American and EMEA volumes are still anticipated to grow into fiscal 2019 with ...
We make no change to our AUD 16.50 fair value estimate for no-moat Orica. There are no changes to long-term assumptions, nor to our AUD 418 million underlying fiscal 2019 earnings forecast. This anticipates continued ammonium nitrate, or AN, volume growth from Australia Pacific, with Bontang plant expansion due to stronger demand, and comes despite well publicised delays from the Burrup plant to first-half 2020. North American and EMEA volumes are still anticipated to grow into fiscal 2019 with ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.